|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Also, mRNA expression of transcriptional marker Nanog and Octamer-binding transcription factor 4 (OCT4), known to enhance malignancy and metastasis in lung adenocarcinoma, was suppressed in ZNF746 siRNA-transfected H460 NSCLC cells.
|
24145959 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Egr1 exerts a promoting effect on cancer metastasis in Oct4-overexpressing lung cancer.
|
31399076 |
2019 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells were analyzed using the marker Oct-4 to improve an understanding of the proliferative ability of cancer stem cells under various pathological conditions, which may lead to the development of novel cancer therapeutics.
|
29142598 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Furthermore, treatment of HB cells with aprepitant led to reduced expression of (liver) stemness markers (AFP, CD13, SOX2, NANOG, and OCT4) and SFA when grown under cancer stem cell conditions.
|
26516161 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line.
|
28454439 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation.
|
21159654 |
2010 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The generation of induced pluripotent stem cells (iPSCs) from somatic cells by expressing ectopic reprogramming transcriptional factors such as Oct3/4, Sox2, Klf4, c-Myc, and Nanog is one of the cutting-edge discoveries in stem cell and cancer research.
|
24568610 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The positive-feedback regulation via OCT4-mediated transactivation of the c-JUN promoter and the c-JUN-mediated transactivation of the OCT4 promoter were crucial for promoting cancer development and maintaining cancer stemness in rG2-DC-1C.
|
27341307 |
2016 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The results suggest that transplantation of such in vitro enriched and expanded OCT4-specific CD8+ CIK cells may improve the specific immune defense mechanism against cancer stem cells, providing a novel avenue of cancer stem cell targeted immunotherapy for clinical treatment of ovarian cancer.
|
28426690 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin/STAT3 pathway in hepatocellular carcinoma.
|
29901157 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer.
|
25609695 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The BORIS-positive cells isolated using BORIS-molecular beacon, expressed higher telomerase hTERT, stem cell (NANOG, OCT4, SOX2) and cancer stem cell marker genes (CD44 and ALDH1) compared to the BORIS-negative tumor cells.
|
25279549 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Treatment of tumor-bearing mice with genotoxic chemotherapy not only prolonged survival and reduced tumor size but also selectively eliminated the OCT4-positive cancer stem cells.
|
29141221 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
However, stemness factors such as Sox2, Oct3/4, and Nanog were related with induced pluripotent stem cells, proposing a correlation between these stemness factors and cancer stem cells.
|
24078401 |
2014 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The data presented, including SCA-1 and Oct4 positivity and the upregulation of stem cell-like genes such as those associated with the Wnt pathway, support the notion that the macrobead selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties.
|
21266363 |
2011 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.
|
23537295 |
2013 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
For PrTIC enrichment, we induced cancer stem cell (CSC) properties in PrCa cells by transducing three defined factors (OCT3/4, SOX2, and KLF4), followed by culture with conventional serum-containing medium.
|
27113741 |
2016 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Stemness state in cancer stem cells (CSCs) was evaluated by the changes of CSC biomarkers including Oct-4 and ABCG2.
|
26289851 |
2016 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
A similar treatment also modulated numerous microRNAs (miRs) including one regulator of Oct4 as well as miRs involved in oncogenesis and/or malignancy, with only a few estrogen-induced miRs.
|
27959387 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Stem cell marker LIN28, related closely with SOX2 and OCT4, has been studied as a biomarker for the maintainance of pluripotent cells in several malignancies.
|
22429493 |
2012 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
This hypothesis is further supported by the recent understanding that: i) cancer is a stem cell disease and OSE is the niche for ovarian cancer stem cells; ii) ovarian OCT4-positive stem cells are regulated by FSH; and iii) OCT4 along with LIN28 and BMP4 are highly expressed in ovarian cancers.
|
25269615 |
2015 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The gene and protein expression levels of pluripotent stem cell markers (Tra-1-60, Oct4, Nanog) and cancer stem cell markers (CD133, CD44) were up-regulated in transduced Rbc51 cells compared to control cells.
|
27856246 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
<b>Objective:</b> Using the gastric cancer cell line SGC7901, we constructed a cell line that overexpressed octamer-binding protein 4 (Oct4) and SRY-box 2 (Sox2) to explore the stem cell oncological and biological characteristics of these cells and to elucidate the mechanisms of Oct4 and Sox2 in cancer.
|
31417271 |
2019 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
These transformed cells, termed as miPS-RM9CM, displayed CSCs properties, including spheroids morphology and expression of both stemness genes and cancer stem cells surface markers, such as Oct3/4, Sox2, Nanog, Klf-4, c-Myc, CD44, and CD133.
|
30210930 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Resistant cell line consisted of a 70% side population fraction enriched with Oct4-positive cancer stem cells.
|
20596658 |
2010 |